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0022-2836/$ - see front matter © 2008 EThere is an ever-increasing demand to select specific, high-affinity binding
molecules against targets of biomedical interest. The success of such
selections depends strongly on the design and functional diversity of the
library of binding molecules employed, and on the performance of the
selection strategy. We recently developed SRP phage display that employs
the cotranslational signal recognition particle (SRP) pathway for the
translocation of proteins to the periplasm. This system allows efficient
filamentous phage display of highly stable and fast-folding proteins, such as
designed ankyrin repeat proteins (DARPins) that are virtually refractory to
conventional phage display employing the post-translational Sec pathway.
DARPins comprise a novel class of binding molecules suitable to comple-
ment or even replace antibodies in many biotechnological or biomedical
applications. So far, all DARPins have been selected by ribosome display.
Here, we harnessed SRP phage display to generate a phage DARPin library
containing more than 1010 individual members. We were able to select well
behaved and highly specific DARPins against a broad range of target
proteins having affinities as low as 100 pM directly from this library, without
affinity maturation. We describe efficient selection on the Fc domain of
human IgG, TNFα, ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) as
examples. Thus, SRP phage display makes filamentous phage display
accessible for DARPins, allowing, for example, selection under harsh
conditions or on whole cells. We envision that the use of SRP phage display
will be beneficial for other libraries of stable and fast-folding proteins.© 2008 Elsevier Ltd. All rights reserved.Keywords: phage display; library generation; SRP phage display; DARPin;
novel scaffoldEdited by F. SchmidIntroduction
The demand for high-quality binding molecules
for biotechnological and biomedical applications is
ever increasing. Antibodies are currently by far the
most frequently used binding molecules, but pro-
teins based on non-immunoglobin scaffolds have
become an appealing alternative.1 From both anti-ess:
lecular Partners AG,
ieren, Switzerland.
igned ankyrin repeat
ctor receptor; ErbB,
ne homolog; HER2,
ptor homolog 2; POI,
nition particle; TNFα,
lsevier Ltd. All rights reservebody and non-antibody scaffolds, bindingmolecules
with high affinity and high specificity against almost
any chosen target protein can be generated in vitro
using appropriately designed combinatorial libraries
in combination with selection technologies such as
phage display or ribosome display.1–4 The success of
such selections is based mainly on the design and
size of the combinatorial library and the selection
technology employed. Together, these factors will
determine the functional size of the library that is
accessible for the selection of binding molecules.
Further important factors are the selection strategy
chosen and the biophysical properties of the target
protein; even with the best library and an optimized
selection protocol it might be very difficult or even
impossible to obtain useful binding molecules
against a "sticky" and unstable target protein.
The underlying principle of all selection technol-
ogies is the physical linkage of the phenotype (i.e. the
displayed protein) and the genotype (i.e. the DNAd.
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technologies use different strategies to achieve this
linkage. The success of any selection experiment
depends on the compatibility of the strategy used
with the proteins to be displayed. Ribosome display,
for example, is a complete in vitro display technology
that relies on the formation of a non-covalent ternary
complex of mRNA, ribosome and the displayed
nascent polypeptide.5 The formation of this ternary
complex by in vitro translation allows the sampling
of very large libraries, and the ease of introducing
mutations by error-prone PCR allows efficient affi-
nity maturation. However, the linkage of the geno-
type and the phenotype is reliably maintained only
under non-denaturing buffer conditions, in the
absence of RNases and at low temperature. In con-
trast, in filamentous phage display,4,6 this linkage is
very robust, allowing a broader range of selection
conditions. Filamentous phage display achieves this
robustness by physically linking the displayed
protein to the surface of a very stable phage particle,7
which encapsulates the corresponding genotype.
Nevertheless, the limiting factor in this selection
technology is the involvement of an in vivo step to
produce the protein displaying phage particles. The
bacterial transformation needed therefore limits the
library size that can reasonably be achieved to
usually much less than 1011 members. Furthermore,
the in vivo assembly process of the phage particle is
not necessarily compatible with any given protein to
be displayed, since its successful translocation to the
periplasm and its folding are also prerequisites. In an
ideal selection experiment, high-affinity binders
should be obtained directly from the library, without
further time-consuming affinity maturations.
The success of a phage selection experiment
depends strongly, as a first parameter, on the size of
the transformed library. In general, the larger the
library, the higher the probability of isolating diverse
binders against a given target protein, and the higher
the affinities of the selected binders.8 For example,
libraries with more than 5 × 109 members were em-
ployed to isolate antibody fragments with sub-na-
nomolar affinities.9–11 Nevertheless, even more
important than the size of the transformed library
(number of independent clones), is the functional
library size; i.e. the number of different and correct
(i.e., full length and folded) molecules available for
selection, as often only a fraction of library members
can be functionally displayed. Three main factors
influence this functional diversity: the above-men-
tioned compatibility of the selection system with the
protein to be displayed; the actual library design; and
the size and quality of the assembled library.
In the case of libraries of designed binding mole-
cules, the use of a very stable scaffold as the starting
point to introduce diversity helps to ensure that
almost all library members are stable and well-
expressed proteins, as diversification of a scaffold
will almost inevitably result in reduced stability in
some library members. Another important aspect is
the design of the diversity, meaning the careful
design of randomized parts into the scaffold; thechallenge is to introduce a level of diversity high
enough to allow successful selection of binders
against any target protein, yet low enough to not
destabilize library members too much.
In the case of designed ankyrin repeat proteins
(DARPins),12,13 which comprise a novel class of
binding proteins, we used consensus design to gene-
rate a very stable scaffold amenable to the introduc-
tion of the needed diversity.14 This consensus design
is based on the sequence and structure analysis of
natural ankyrin repeat proteins and allows the
delineation of framework residues, which are
important for stability of the scaffold, and the defini-
tion of potential target interaction residues (inspired
by the study of natural ankyrin complexes) suitable
to introduce the needed level of diversity. Indeed,
most members of such DARPin libraries have very
favorable biophysical properties.13 They are very
well expressed, monomeric in solution, highly
soluble, thermodynamically stable and show fast
cooperative folding behavior.15
From such DARPin libraries, specific binders with
high affinities have been selected for a broad range of
target proteins by using ribosome display.16–20
Nevertheless, and much to our initial surprise, the
display of DARPins on filamentous phage was high-
ly inefficient using conventional systems, despite the
good biophysical properties of the proteins. We
identified this problem as one of inefficient transloca-
tion of the DARPins into the periplasm due to their
premature folding in the cytoplasm when using the
post-translational Sec pathway, and one that can be
solved by using the signal recognition particle (SRP)
translocation pathway for phage display.21
In SRP phage display,21 the proteins to be dis-
played are directed to the Escherichia coli cotransla-
tional SRP translocation pathway by using an
appropriate signal sequence, whereas conventional
phage display uses the post-translational Sec trans-
location pathway. This simple change in the use of
the translocation route by changing the signal se-
quence seems to prevent premature folding of stable
and fast-folding proteins in the cytoplasm and there-
fore allows their efficient translocation and subse-
quent display on filamentous phage particles. These
results indicated that the use of SRP phage display
may help to obtain phageDARPin librarieswith high
functional diversity, leading to efficient selections.
Here, we describe the generation of a large phage
DARPin library by using SRP phage display, selec-
tions on a panel of target proteins using this library
and analysis of the selected DARPins. In addition, we
discuss the potential of SRP phage display to generate
novel binding molecules with very desirable proper-
ties for biotechnological or biomedical applications.
Results
Construction of the phage DARPin library
The phage DARPin library described here is based
on the phagemid vector pPDV1 that allows the dis-
1213Selection of DARPins with Sub-nanomolar Affinitiesplay of a protein of interest (POI) fused to the minor
phage coat protein 3 (p3) on filamentous phage
(Supplementary Data Fig. 1). In contrast to most
other phage display vectors, it fuses the POI to a
signal sequence using the cotranslational SRP path-
way for translocation of the POI-p3 fusion across the
cytoplasmic membrane of E. coli. The use of the SRP
pathway ensures the efficient display of stable and
fast-folding DARPins on phage particles.21
We used the N3C DARPin library13 (N3C denotes
an N-terminal capping repeat, three randomized
internal repeats, and a C-terminal capping repeat)
and brought it to the phage display format by PCR
amplification and subcloning it into pPDV1. E. coli
XL1-Blue cells were transformed with the library
yielding 2.6 × 1010 independent colonies (trans-
formed library size; see Material and Methods for
details). The transformed E. coli XL1-Blue cells were
infected with helper phage VCS M13, and subse-
quently IPTG was added to the culture to induce the
expression and thus the display of the DARPins on
the phage particles. For all initial rounds of selection,
as described below, the input library phage particles
were used directly from a frozen phage library
stock. There was no need to re-amplify the library to
obtain functional display, as the DARPins displayed
on phage particles seem to tolerate at least one
freeze–thaw cycle very well.
High-level functional diversity of the phage
DARPin library
The functional diversity of the transformed
2.6×1010 independent clones of the DARPin library
was assessed by sequencing, determining the dis-
play level and subsequent cytoplasmic expression
analysis. DNA sequencing of 55 randomly picked
clones showed that 26 (47%) encode functional
DARPin sequences, composed of 18 (33%) N3C, 7
(13%) N2C and 1 (2%) N1C DARPin library mem-
bers, all with different amino acids at randomized
positions. The presence of library members having
less than three internal repeats (N1C and N2C) can
be attributed to in vitro recombination during library
construction, requiring the PCR amplification of the
DARPins, and result from their repetitive nature.
Importantly, DARPins of different length can all be
functional. The remaining 29 (53%) clones had
frameshifts, deletions or insertions in the DARPin
sequence or contained no insert at all (non-func-
tional part of the library). Phage particles produced
from the same 55 clones of the library as sequenced
above were analyzed for DARPin display by Wes-
tern blot. All 26 (47%) clones correct at the sequence
level showed bands at the size expected for a
DARPin-p3 fusion protein and signal intensities
similar to the signal obtained for a well-folding
antibody scFv fragment using a standard phagemid
for monovalent display. From this comparison, it can
be assumed that, with the current system, single
DARPins are displayed on about 1–10% of phage
particles.22 This is a good balance between an effi-
cient yet largely monovalent display.To analyze cytoplasmic expression of the DAR-
Pins, a pool of DARPin inserts from the library was
subcloned into pDST67 (seeMaterials andMethods),
a vector for high-level, soluble cytoplasmic expres-
sion derived from pQE30 (QIAgen), followed by
small-scale expression in 96-deep well plates and
SDS-PAGE analysis of 57 randomly picked clones
that were not sequenced. Thirty-two (56%) of the
clones showed expression levels of soluble DARPins
above 0.1 mg/ml E. coli culture. Together, these
results showed that all clones that are correct at the
amino acid level are well displayed on the phage
particles and can be expected to be well expressed in
the cytoplasm. Thus, we can estimate that the phage
DARPin library contains about 1.2×1010 correct
clones, which encode well-behaved displayable
molecules (functional library size, 47% of the trans-
formed library size), taking into account that the
library used as template contained at least 1010 indi-
vidual members.16
As with any randomized protein library, the non-
functional part of the library may sometimes lead to
the enrichment of background binding clones en-
coding defective molecules that have parts of the
scaffold replaced by unstructured and sticky poly-
peptides. In all cases, this background enrichment
could be prevented by applying the optimized selec-
tion protocol described in detail in the Supplemen-
tary Data.
Target protein preparation, immobilization and
optimized selection protocol
For the validation of the phage DARPin library, we
performed selections against a broad range of purified
target proteins (Table 1). To avoid partial protein
denaturation of the target due to direct immo-
bilization on solid plastic (i.e. polystyrene) surfaces,
samples of all target proteins were chemically or
enzymatically (using an Avi-tag 23) biotinylated. This
allows selections to be performed either on biotiny-
lated target protein bound to neutravidin or strepta-
vidin, which are immobilized directly on a solid
plastic surface (referred to as an “immobilized target
protein”) or on biotinylated target protein in solution,
which was subsequently captured with streptavidin-
coated beads (referred to as a “target protein in
solution”). From the analysis of a number of selection
experiments, we found that the most efficient enrich-
ment of specific binders from our phage DARPin
library is obtained with an optimized selection
protocol that is composed of a first round of selection
on immobilized target protein, followed by one or
two further rounds of selection on target protein in
solution. (The development of this optimized selec-
tion protocol is described in the SupplementaryData.)
Unless stated otherwise, selectionswere done at room
temperature. Enzyme-linked immunosorbent assay
(ELISA) experiments were performed on biotinylated
target protein bound to neutravidin, which had been
immobilized directly on a solid plastic surface, and by
using non-biotinylated target protein for competition
experiments. The different selection approaches need-
Table 1. Description of target proteins used for the selectionsa
Target protein Abbr.
Selected
binderb Descriptionc
Accession
numberd
Fc of huIgG1 huIgG1_Fc I_xx P100 – K330 of human IgG1 (Fc domain) SP:P01857
TNFα TNFα T_xx A76– L233 of human tumor necrosis factor precursor (TNFα) SP:P01375
ErbB1 (1–501)e ErbB1 E_xx L25 – S525 of human receptor tyrosine-protein kinase
ErbB1 fused to huIgG1_Fc
SP:P00533
ErbB2 (1–631)e ErbB2–631 H_xx S22 – T652 of human receptor tyrosine-protein kinase ErbB2 SP:P04626
ErbB2 (1–509)e ErbB2–509 9_xx S22 – N530 of human receptor tyrosine–protein kinase ErbB2 SP:P04626
ErbB4 (1–500)e ErbB4 B4_xx Q26 – R525 of human receptor tyrosine–protein kinase
ErbB4 fused to huIgG1_Fc
SP:Q15303
a Abbreviations used: Fc, fragment crystallizable; IgG1, immunoglobulin G1.
b Nomenclature of selected binders, xx corresponds to the number of a specific binder.
c The first and last amino acid used as denoted in the respective Swiss-Prot reference are indicated in single-letter amino acid code.
d Accession number: SP, Swiss-Prot.
e ErbB receptors and in parentheses the amino acids of the mature extracellular domain as described.47
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tions of the binders obtained are describedbelow. This
partial listing illustrates the versatility of the library,
and the great influence of the target protein on the
peculiarities of the selection. While high-affinity and
specific binders could be obtained in every case, we
chose these particular examples to illustrate our cha-
racterization, aswell as some challenges and solutions
to problems.
Efficient selection of DARPins specific for
huIgG1_Fc
Binders against the Fc domain of antibodies are of
interest as an in vitro detection reagent, and for
biomedical applications (e.g., to extend the in vivo
half-life of molecules fused to such a binder by
attaching to antibodies present in the blood stream).
To enrich binders against the Fc domain of human
IgG1 (huIgG1_Fc, Table 1) we performed three
rounds of selection using our optimized selection
protocol as described above. From each selection
round we analyzed the recovered and amplified
polyclonal pool of phage particles for target binding
by phage ELISA. Enrichment of phage particles
displaying target specific DARPins was already
observed after the second selection round with a
strong increase after the third round, and no back-
ground enrichment of phage particles binding to the
corresponding non-target-coated matrix was ob-
served (Fig. 1a).
To screen individual DARPins for binding to their
target protein, and at the same time eliminate any
conceivable dependence on the p3-fusion format, we
did not carry out single-clone analysis with phages
but subcloned directly the selected pool of binders
from round 3 into the cytoplasmic expression vector
pDST67. From 94 individual DARPins analyzed for
full-length huIgG1 binding by a crude extract ELISA
(see Materials and Methods), 82 gave a specific
binding signal (signal/background N 10) (Fig. 1b;
Table 2). Crude cell extracts of ELISA-positive clones
were further analyzed by SDS-PAGE (Fig. 1c),
confirming that, in general, the excellent expression
properties of DARPins aremaintained throughout. It
should be noted that some DARPins having morethan two internal repeats run at lower apparent
molecularmass or show additional bandswith faster
running behavior. The same behavior was observed
for the respective purified proteins, even though
they were subsequently shown by DNA sequencing
andmass spectrometry to be precise in sequence and
not degraded. As shown previously,13,21 this is due
to an incomplete denaturation of these stable
molecules by SDS in the loading buffer, even after
boiling. N2CDARPins do not have this extreme SDS-
resistance anddomigratewhere expected, consistent
with the observed increase in stability with the
number of repeats.15 On the basis of the ELISA
signals, 21 clones were submitted for sequencing,
resulting in eight different sequences of DARPins
confirmed by replicate ELISA experiments to bind
the target protein (data not shown). The six most
promising candidates (Table 2), named I_02, I_07,
I_13 (N2C library members), and I_01, I_11, I_19
(N3C library members) were analyzed further.
Expression and immobilized metal ion chromato-
graphy (IMAC) purification was performed in 96-
well format in parallel with binders selected against
other target proteins (see Materials and Methods),
yielding on average more than 1 mg of N 95% pure
protein for each clone from 8 × 1.3 ml E. coli culture.
These purified DARPins were used for all further
experiments.
To investigate the specificity of the selected
DARPins, ELISA experiments with the four high-
affinity clones I_01, I_02, I_07 and I_19 (Fig. 1c) and
the two lower-affinity clones I_11 and I_13 (Fig. 1d)
were performed. All of the binders do show specific
binding to full-length human IgG1 (huIgG1) but do
not bind to neutravidin, mouse IgG1 (muIgG1) or
mouse IgG2b (muIgG2b). In the competition ELISA
setup, the binding to immobilized huIgG1 could be
well inhibited by preincubation of the DARPins
with free huIgG1 (Fig. 1c and d). From the con-
centrations of free huIgG1 needed for an inhibition
of N 50%, the affinities of these binders can be esti-
mated to be in the nanomolar range, as could be
confirmed by surface plasmon resonance (SPR, see
below).
The binders were further characterized by size-
exclusion chromatography (SEC) and compared to
Fig. 1. Selection, screening and characterization of binders against huIgG1_Fc. (a) The enrichment for the selection
performed on huIgG1_Fc was analyzed by phage ELISA. Equivalent amounts of the initial library (Lib) and pools of
amplified phage particles from each selection round R1i, R2s and R3s (subscript i denotes selection on immobilized target
protein, subscript s denotes selection on soluble target protein) were tested for binding to immobilized streptavidin,
neutravidin and immobilized huIgG1_Fc. The signal of bound phage particles, detected with an anti-M13 antibody, is
shown for each sample applied. (b) ELISA screening to identify DARPins with affinity for huIgG1_Fc. E. coli extracts of
randomly picked clones expressing soluble DARPins of selection round 3 were analyzed for binding to immobilized full-
length huIgG1 and BSA (control). Positions A1 – A10 and B1 – B9 of a 96-well plate are shown. (c) SDS-PAGE analysis of
the E. coli extracts used in (b) for ELISA screening. The mass of the SDS-PAGE protein markers is indicated in kDa. (d)
ELISA with high-affinity huIgG1_Fc binders. To analyze specificity, 1 nM solutions of the purified DARPins I_01, I_02,
I_07 and I_19 were tested for binding to neutravidin, huIgG1, mouse IgG1 (muIgG1) and mouse IgG2b (muIgG2b). In
parallel, competition was tested by incubation of 1 nM solutions of the DARPins with 10 nM or 100 nM free huIgG1
before binding on immobilized huIgG1. (e) ELISA with low-affinity huIgG1_Fc binders and control DARPin E3_5. To
analyze specificity, 5 nM solutions of the binders I_11, I_13 and control DARPin E3_5 were tested for binding on
neutravidin, huIgG1, muIgG1 and muIgG2b, and in parallel, competition was tested by incubation of 5 nM solutions of
the DARPins with 100 nM or 500 nM of free huIgG1 before binding on immobilized huIgG1. All full-length IgGs were
immobilized directly on solid supports. The first word in the legend denotes the protein immobilized, no comp. denotes
the absence of a competitor and + huIgG1 denotes the presence of competitor in concentrations of 10 nM, 100 nM or
500 nM.
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At a concentration of 10 μM, four of the six clones
tested eluted at the size expected for the monomer
(Fig. 2). Clone I_19 showed a second elution peak at
lower elution volume, indicating some dimer
formation at this concentration. I_01 eluted as a
single peak but at lower elution volume (higher
apparent molecular mass) than expected, indicating
an increased hydrodynamic radius due to multi-
merization or partial unfolding. Further analysis of
this binder by SEC combined with multi-angle light-
scattering (SEC-MALS) revealed a clearly dimeric
mass of the DARPin I_01.
Four of the clones were further analyzed by SPR
(Table 3 and Supplementary Data Fig. 2) and the
data obtained were evaluated with a global kinetic
fit. I_19 had the highest affinity for huIgG1_Fc (KD=
2.1 nM) and I_11 the lowest affinity (KD= 137 nM),in good agreement with the competition ELISA
experiments performed. To calculate the affinity of
I_19, we assumed that the DARPin would be
completely monomeric at all concentrations used
for the SPR measurements (the maximal concentra-
tion of DARPin was 75 nM), and the global fit
agrees very well with a 1:1 interaction (see Supple-
mentary Data). The sequences are shown in Supple-
mentary Data Fig. 3.
In summary, we were able to enrich a diverse set
of highly specific binders with affinities in the low
nanomolar range in just three rounds of selection,
from our phage DARPin library.
Selection of DARPins binding to TNFα
Antibodies to TNFα have been developed for a
number of therapeutic applications,24 as has the
Table 2. Summary of the phage selection of DARPins against different target proteins
Target protein Round of selection
No. positive
clonesa
No. different
sequencesb Binders further analyzed in this study
huIgG1_Fc R3 82/94 8/21 I_01/02/07/11/13/19
TNFα R2/3c 102/188 29/52 T_01/02/07/08/09/16/25/27/37/40
ErbB1 R2/3d 97/369 1/64 E_01
ErbB1 R1 (epitope-masking)e 81/105 4/20 E_67/68/69
ErbB2–509 R3 83/94 13/29 9_16/26/29
ErbB2–631 R1 (epitope-masking)e 24/94 8/16 H_14
ErbB4 R3 55/143 5/48 B4_01/02/07/33/45
ErbB4 R1 (epitope-masking)e 84/94 6/20 B4_50/58
CitSf R3/4 110/124 11/21 cp34_15/16f
a Ratio of the number of positive clones to the total number of clones screened by ELISA.
b Number of clones with different sequences confirmed by ELISA using purified DARPins to bind the target protein, identified in the
total number of clones sequenced.
c Sum of the analysis of the second and third round of selection.
d Sum of the analysis of the second and third round of different selection approaches.
e One round of selections with epitope-masking using preselected pools as input as described in Results.
f Huber et al. 37
1216 Selection of DARPins with Sub-nanomolar Affinitiessoluble recombinant receptor of TNFα, Etanercept
(Enbrel™, see below),25 and binding molecules
based on novel scaffolds are currently being devel-Fig. 2. Size-exclusion chromatography (SEC) of se-
lected DARPins. The chromatograms of the six huIgG1_Fc
binders and the unselected DARPin E3_5 are shown as
examples. For eachDARPin, the number of repeats stacked
between N-Cap (N) and C-Cap (C) is given in parentheses.
The molecular mass standards, phage protein D (gpD)
with a mass of 17.6 kDa and phage protein SHP, a trimer
with a mass of 50.2 kDa, are indicated by arrows.oped to do the same. To enrich binders specific for
the soluble trimeric form of TNFα (Table 1) we
performed selections and screenings as described
above for huIgG1_Fc using biotinylated TNFα (see
Materials and Methods). Fast enrichment of phage
particles displaying DARPins specific for TNFαwas
already observed after the second selection round.
From rounds 2 and 3, 94 individual DARPins each
were screened by crude extract ELISA for TNFα
binding, giving 15 and 87 specific binding signals,
respectively (Table 2). On the basis of the ELISA
signals, 52 clones were submitted for sequencing,
resulting in a highly diverse set of 29 different
sequences of DARPins; interestingly, all selected
DARPins were of the N3C type. Binders were
expressed in the cytoplasm, purified by IMAC and
further analyzed by SEC; they show high-level ex-
pression and most of them have monomeric elution
behavior, similar to the results obtained for the
huIgG1_Fc binders described above.
We used ELISA to investigate the specificity of the
selected DARPins (Fig. 3). All of the binders showed
specific binding to TNFα, no interaction with neu-
travidin, and in the competition ELISA setup the
binding to immobilized TNFαwas well inhibited by
preincubation of the DARPins with free TNFα. From
the competition ELISA signals obtained with 10 nM
free TNFα, the affinities of the binders were esti-
mated to be in the low nanomolar range. Interesting-
ly, the binding of all selected DARPins is inhibited
almost completely by preincubation of the immobi-
lized TNFα with Etanercept (Enbrel™, recombinant
human soluble tumor necrosis factor alpha receptor
fused to the Fc domain of human IgG1, Amgen,
USA) (Fig. 3).
During further analysis, very much to our surprise,
we discovered that the selected DARPins show
specific TNFα binding that is dependent on the
detergent Tween-20 that was present during the
selection. We did not analyze this particular set of
DARPins further, sincewe do not expect them to bind
their target protein in vivo. To prevent the enrichment
Table 3. Affinities and binding kinetics of DARPins
Target protein Clone (NxC)a
Oligomerization
statusb KD (nM) kon (10
5 M−1s−1) koff (10
−3s−1)
ErbB1c E_01 (N3C) m 0.5 4.4 0.2
E_67 (N3C) m 7.3 0.3 0.2
E_68 (N3C) m/d 0.7 26 1.9
E_69 (N4C) m 15 0.7 1.1
ErbB2–509c 9_16 (N3C) m 6.9 1.2 0.9
9_26 (N3C) m 1.4 0.7 0.1
9_29 (N3C) m 3.8 2.0 0.8
ErbB2–631d H_14 (N3C) m 0.2 4.1 0.1
ErbB4c B4_01 (N4C) m 0.1 7.3 0.06
B4_02 (N3C) m 0.4 1.2 0.05
B4_50 (N4C) m 0.3 35 1.0
B4_58 (N5C) m/d 9.0 16 14
IgG1_Fcc I_02 (N2C) m 41 2.8 12
I_07 (N2C) m 25 0.7 1.7
I_11 (N3C) m 140 4.9 67
I_19 (N3C) m/d 2.1 3.4 0.7
CitSe cp34_15 (N3C) m 5.4 – –
cp34_16 (N3C) m 1.3 – –
a Name of the respective clone and, in parentheses, the number of internal repeat modules (x) stacked between the N-Cap (N) and the
C-Cap (C).
b Oligomerization status (monomer, m; dimer, d) of the DARPins determined by SEC, using globular proteins as molecular mass
standards, and comparing them to other DARPins, whose oligomerization status had been verified by multi-angle light-scattering.
c Association (kon) and dissociation (koff) rate constants were measured by surface plasmon resonance, and the respective dissociation
constant KD was calculated as (koff/kon). Plots of the kinetic data, evaluation with a global kinetic fit and statistical error in the parameters
are given in Supplementary Data Fig. 2.
d C. Jost and A.P., unpublished results.
e Dissociation constants KD were measured by equilibrium titration (BioVeris).
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1217Selection of DARPins with Sub-nanomolar Affinitiesof such binders, Tween-20 can be omitted or replaced
by other detergents in new selection approaches on
TNFα.
Selection of DARPins to members of the ErbB
receptor family
Antibodies to ErbB1 (EGFR) and the other mem-
bers of the ErbB receptor family, notably ErbB2
(HER2), are being developed as anti-tumor thera-
peutics.26 Here, we describe the selection of DARPin
binders against ErbB1, ErbB2 and ErbB4. The
extracellular part of all members of this family isFig. 3. ELISA of selected TNFα-binding DARPins. To analy
tested for binding on neutravidin, immobilized TNFα and im
Etanercept (Enbrel™, recombinant human soluble tumor necro
IgG1). In parallel, competitionwas tested by incubation of 5 nM
before binding on immobilized TNFα. Only a subset of the sele
was used as control. The first word in the legend denotes th
competitor and + TNFα or + Enbrel denotes the presence of cocomposed of four domains (I–IV).27 The selections on
ErbB2 are described below. For both ErbB1 and
ErbB4, the extracellular domains I–III of the respec-
tive receptor fused to huIgG1_Fc were used in
selections (see Table 1). (The different selection
approaches performed on these two target proteins
are described in detail in the Supplementary Data.)
Individual DARPins were screened for specific
target protein binding by crude extract ELISA as
described for huIgG1_Fc. For ErbB1, 97 out of 369
and for ErbB4, 55 out of 143 screened clones gave a
specific binding signal (Table 2). On the basis of
ELISA signals 64 clones for ErbB1 and 48 clones forze specificity, 5 nM solutions of the selected DARPins were
mobilized TNFα preincubated with an excess (500 nM) of
sis factor alpha receptor fused to the Fc domain of human
solutions of the DARPinswith 10 nM or 100 nM free TNFα
cted TNFα binders is shown, and unselected DARPin E3_5
e protein immobilized, no comp. denotes the absence of a
mpetitor (respective concentrations given in nM).
Fig. 4. Equivalent amounts of the input and output
phage particles from one round of epitope-masking
performed on ErbB1 (by adding soluble DARPin E_01)
and on ErbB4 (by adding soluble DARPin B4_02) were
analyzed by phage ELISA as described for Fig. 1.
Additionally, binding was tested on the respective target
protein preincubated with an excess of the respective
DARPin (ErbB1 + E_01 or ErbB4 + B4_02). Subscript s
denotes selection on target protein in solution. The first
word in the legend denotes the protein coated, no comp.
denotes the absence of a competitor and + E_01 or + B4_02
denotes the presence of 2 μM DARPin competitor.
1218 Selection of DARPins with Sub-nanomolar AffinitiesErbB4 were submitted for sequencing. Surprisingly,
this resulted in only one dominant ErbB1 binder
(E_01) and five ErbB4 binders (B4_01, B4_02, B4_07,
B4_33 and B4_45), of which B4_02was strongly over-
represented among the sequenced clones (∼ 66 %).
To increase the diversity of the selected binders
and to avoid dominant enrichment of these binders,
we used a selection procedure termed epitope-mask-
ing.28 For this purpose, we expressed and purified
the two dominant binders (E_01 and B4_02) by
IMAC and performed one round of selection on the
two target proteins in solution in the presence of an
only twofold excess of the respective purified binder.
By this partial masking of the epitope of the domi-
nant binder we expected to select DARPins that re-
cognize a different epitope, but at the same time, still
allow the selection of new high-affinity DARPins
competing for the same epitope. Using higher con-
centrations of the competitor resulted in a lower
diversity of the selected binders (see below). For the
target proteins ErbB1 and ErbB4, equivalent
amounts of amplified, partially enriched pools of
phage particles after selection round 1 on immobi-
lized target proteins (Supplementary Data Fig. 4(a)
and 4(b)) and after selection round 2 on target
proteins in solution (Supplementary Data Fig. 4(c)
and 4(d)) were used as input. After one round of
selection, input and output pools of phage particles
were analyzed by phage ELISA for binding to their
target protein in the absence and in the presence of a
large excess (2 μM) of the respective dominant
binders (Fig. 4a and b). For ErbB1, the binding signal
obtained on target protein alone was much higher
than the signal obtained on ErbB1 in the presence of
the DARPin E_01, indicating that most of the
DARPins selected indeed recognize the same or an
epitope overlapping with that of DARPin E_01 (Fig.
4a). In contrast, for ErbB4, the binding signal
obtained on target protein alone or in the presence
of B4_02 was identical, indicating that in this case,
most of the selected DARPins recognize an epitope
different from that of DARPin B4_02 (Fig. 4e).
To analyze the success of the epitope-masking,
individual selected DARPins were first screened for
binding to their target protein by crude extract
ELISA as described for huIgG1_Fc. For ErbB1, 81 of
105, and for ErbB4, 84 of 94 screened clones gave a
specific binding signal (Table 2). On the basis of the
ELISA signals, 20 clones of each selection were
submitted for sequencing, resulting in four new
binders for ErbB1 and six new binders for ErbB4.
Binders were expressed in the cytoplasm of E. coli,
purified and analyzed further by SEC. They show
high-level expression and most of them have
monomeric elution behavior, similar to the results
obtained for the huIgG1_Fc binders described above.
All of the clones bound specifically to the respective
target protein, as shown by competition ELISA, but
only those ErbB1 binders (E_67, E_68, E_69) and
ErbB4 binders (B4_50, B4_58)were analyzed in detail
whose ELISA signals could be inhibited to less than
50% with 10 nM (50 nM for E_69) ErbB1 or ErbB4 as
competitor, suggesting a high affinity (cf Fig. 1d).This was confirmed by SPR analysis (see below).
(The sequences are shown in Supplementary Data
Fig. 3.)
Clones selected by epitope masking show
diverse specificities
Binding and epitope localization of the clones
selected by epitope masking were tested by ELISA.
All high-affinity ErbB1 and ErbB4 binders were
tested for interactionwith the respective biotinylated
target protein bound to immobilized neutravidin, or
the nonbiotinylated target protein bound to the
immobilized DARPins (E_01 or B4_02, respectively)
used for epitope-masking (Fig. 5a and b). In the
selection on ErbB1 using an only twofold excess of
E_01, three new high-affinity clones were selected.
E_69 recognized an epitope not competing with
E_01, whereas the other two binders, E_67 and E_68,
must recognize a competing epitope, as they could
not bind to their target, immobilized over E_01.
Fig. 5. ELISA of selected ErbB1 and ErbB4 binding DARPins. A 50 nM solution of the selected ErbB1 (a) and ErbB4 (b)
binders was tested for interaction with immobilized target protein (ErbB1 or ErbB4, respectively), target protein bound to
immobilized DARPin used for epitope-masking during the selection round (E_01—ErbB1 or B4_02—ErbB4, respectively),
and neutravidin. (c, d) Specificity was tested by applying a 50 nM solution of the selected ErbB1 binders (c) and ErbB4
binders (d) on immobilized ErbB-receptors (ErbB1, ErbB2-631 and ErbB4) and neutravidin. Unselected DARPin E3_5 was
used as control in all experiments. ErbB1 binders E_67, E_68 and E_69 and ErbB4 binders B4_50 and B4_58 were selected
by epitope masking.
1219Selection of DARPins with Sub-nanomolar AffinitiesWhen performing the same epitope-masking selec-
tion in the presence of a much higher excess (20-fold)
of the masking DARPin (E_01), clone E_69 was very
dominant. This finding shows that somewhat higher
levels of diversity can be obtained by only partially
masking the dominant epitope than by completely
blocking it. In contrast, for ErbB4, one of the clones
(B4_01) selected on ErbB4 in solution and both of the
clones selected by epitope-masking recognized an
epitope other than B4_02. None of the binders
showed cross-reactivity when analyzed in ELISA
experiments for binding to other receptors of the
ErbB-family (ErbB1, ErbB2 and ErbB4), which share
about 50% sequence identity and have highly
conserved structures (Fig. 5b and c). To estimate
affinity, competition experiments with ErbB1 and
ErbB4 were performed as described for huIgG1_Fc,
and ELISA binding signals were inhibited to less
than 50% by 10 nM competitor (50 nM for E_69),
suggesting low nanomolar affinity (data not shown).
This was confirmed by SPR analysis (see below).
Four well-behaved clones for each of the target
proteins were further analyzed by SPR (Table 3 and
Supplementary Data Fig. 2) and the data were eva-
luated with a global kinetic fit. Five of the measured
binders showed affinities in the picomolar range, and
the other binders were all below 15 nM.
In conclusion, dominant epitopes on a target pro-
tein may hinder the direct selection of diverse bind-
ers. This “hidden“diversity present in the library canbemade accessible bymasking the dominant epitope
during the selection cycle. Strongmasking, however,
can lead to a new focusing of the library.
Epitope removal allows selection of more
diverse DARPins
To enrich binders against ErbB2 containing all
four domains (I – IV) of the extracellular part of the
receptor and thus comprising the first 631 amino
acid residues of the mature protein (termed ErbB2-
631, see Table 1), we performed three initial rounds
of selection on the target protein in solution. Good
enrichment of phage particles displaying DARPins
binding to ErbB2-631 but not to ErbB2-509 (see
Table 1), which comprises only the first 509 amino
acid residues of the mature protein and therefore
lacks domain IV, was observed after the third se-
lection round, as shown by phage ELISA (Fig. 6a).
This is in good agreement with previously per-
formed ribosome display selections, where all
selected high-affinity binders recognized domain
IV, which seems to contain one or more dominant
epitopes of that protein.20
We used two strategies to obtain binders that re-
cognize domains I – III of the target protein. First, we
performed selection directly on ErbB2-509. Surpris-
ingly, at room temperature, all of the selection
approaches on ErbB2-509, independent of whether
the selection had been performed on immobilized
Fig. 6. The enrichment for the selections performed on
ErbB2-631 in solution at room temperature and on ErbB2-
509 at 4 °C were analyzed by phage ELISA. Equivalent
amounts of the initial library (Lib) and pools of amplified
phage particles from each selection round (R1, R2, and R3)
were tested for binding to immobilized streptavidin,
neutravidin and immobilized ErbB2-509 and ErbB2-631.
The signal of bound phage particles, detected with an anti-
M13 antibody, is shown for each sample applied. For each
round, the subscript denotes if the selectionwas performed
on immobilized target protein (i) or on target protein in
solution (s).
1220 Selection of DARPins with Sub-nanomolar Affinitiestarget protein or on target protein in solution, failed
to yield an enrichment of target-specific DARPins.
We reasoned that this might be due to a lower
stability or higher flexibility of the truncated version
of the receptor at room temperature and therefore
performed further selections at 4 °C. Indeed, after
three rounds of selection on ErbB2-509 by using the
optimized selection protocol at 4 °C, target-specific
binding of the enriched pools was observed in
phage ELISA (Fig. 6b). For the pool of round 3,
specific binding to both target proteins ErbB2-631
and ErbB2-509 was observed, suggesting that
domains I–III are recognized, and that target
stability is indeed a very important parameter for
optimal selections.
After round 3, 94 individual DARPins were
screened by crude extract ELISA for binding to
ErbB2-509, resulting in 83 specific binding signals
(Table 2). On the basis of the ELISA signals, 29
binders were sequenced, resulting in a diverse set of
13 different sequences of DARPins. Binders were
expressed in the cytoplasm, purified and analyzedfurther by SEC; they showed high-level expression
and most of them have monomeric elution behavior
in SEC, similar to the results obtained for the
huIgG1_Fc binders described above.
ELISA experiments showed high specificity (no
cross-reactivity with ErbB1 and ErbB4), and inhibi-
tion of ELISA signals to less than 50% was observed
for more than half of the clones using 10 nM ErbB2
as competitor, suggesting nanomolar affinity (cf Fig.
1d). Three of the binders (9_16, 9_26, and 9_29) were
analyzed further by SPR showing affinities in the
low nanomolar range (Table 3). (The sequences are
shown in Supplementary Data Fig. 3.)
The results obtained indicate that, similar to the
epitope masking strategy described above, this
strategy of removing an epitope by deleting a
domain makes the hidden diversity of the library
accessible for selection. It shows also that attention
must be paid to the conformational integrity of the
target protein, in this case by lowering the tempera-
ture during selection.
Additionally, as described for ErbB1 and ErbB4,
we partially masked one of the epitopes (see above)
on domain IV by adding a twofold excess of the
high-affinity DARPin H10-2-G3 in one round of se-
lection on ErbB2-631.29 The amplified, partially en-
riched pool of phage particles after two rounds of
selection on the target protein in solution (Fig. 6a)
was used as input. Screening of 94 clones by crude
extract ELISA resulted in 24 specific binding signals.
On the basis of the ELISA signals, 16 binders were
sequenced, resulting in eight different sequences, of
which four had been found in the selection on
ErbB2_509. Of the three new binders, two recog-
nized ErbB2-509 as well as ErbB2_631 (domain I–III
binders) and one (H_14) recognizes only ErbB2_631
(domain IV binder). Due to its exceptionally high
binding signal, binder H_14 was analyzed further
by SPR and the data were evaluated with a global
kinetic fit showing an affinity in the picomolar range
(Table 3) (C. Jost and A.P., unpublished results).Discussion
Large functional DARPin library obtained by
SRP phage display
The quality of a combinatorial library of binding
proteins can be functionally described by the ability
to isolate high-affinity binders against a broad set of
target proteins. Three major factors contribute to
successful selections from such a library. First, the
library design, which encompasses the scaffold used
as well as the diversification strategy employed.
Second, the theoretical diversity of the combinatorial
DNA library, combined with the library quality, i.e.,
the percentage of clones that actually have sequences
as specified in the design. Finally, the display
technology chosen, which should ensure that the
members of the library are presented in a functional
form, allowing for efficient selection. Together, these
1221Selection of DARPins with Sub-nanomolar Affinitiesfactors determine the functional diversity of the
library that is accessible for the selection of binding
molecules by the technology employed.
We have developed SRP phage display that allows
the efficient display of fast-folding and stable
proteins such as DARPins that are virtually refrac-
tory to conventional phage display that uses Sec-
dependent translocation of the POI into the peri-
plasm.21 We generated our phage DARPin library
using the previously described combinatorial N3C
DARPin library13,16 as template and a phagemid
containing an SRP-dependent signal sequence.21
Analysis of single unselected members of this new
library revealed that all clones that are correct at the
sequence level are displayed on the phage particles
at levels comparable to the display yield obtained for
a well-expressed single-chain Fv (scFv) antibody
fragment using a conventional phagemid with a Sec-
dependent signal sequence. We thus obtained a
functional library diversity of at least 1×1010 which
is comparable to the size reported for the largest
phage libraries displaying non-immunoglobulin
domains30 and comparable to the size of large
phage libraries displaying antibody fragments.8
The functional part of the phage DARPin library is
composed of N1C (4%), N2C (27%) and N3C (69%)
DARPins, as determined from the sequencing and
display analysis of unselected clones. The constructs
shorter than the N3C are probably side-products of
the PCR of the initial combinatorial N3C library
necessary during construction; this is also observed
regularly when doing ribosome display selections
and results from the repetitive nature of DARPins.
Interestingly, we even selected N4C and N5C
DARPins (Table 3). Since no repeat duplication or
deletion that would indicate in vivo recombination of
the DARPin scaffold was ever observed, we expect
these longer constructs, just as the shorter ones, to be
already present at a low level in the initial library.
Since the selection for binding works well, as
demonstrated by the successful selection against
diverse targets, the occurrence of DARPins with a
different number of repeats, (presumably) already in
the initial library, can be seen as a source of additional
diversity. A larger contiguous patch of randomized
residues in the DARPins with more than three
randomized repeats may allow binding to additional
epitopes, where contacts by residues in the capping
repeats might not have been favorable or where a
larger binding surface is needed. An accumulation of
these longer constructs during selections with epi-
tope masking supports this theory.
In just two or three phage display selection rounds
we were able to select high-affinity binders against a
broad range of target proteins in all cases attempted
so far (Table 2). This validates the functional library
diversity and the optimized diversity design of the
DARPin scaffold, and that SRP phage display is
robust to select specific binders from this library.
Good performance of SRP phage displaywas recently
reported for the display of a library based on the
fibronectin type III domain.31 We suppose that SPR
phage display could increase the functional diversityof many other libraries, especially those expected to
be composed of similarly stable and fast-folding
scaffolds or those containing members with widely
different folding rates and stabilities, such as
expected, for example, in cDNA libraries.
It should be noted that for SRP phage display, as
reported for conventional phage display,32 it might
be necessary to optimize the phagemid in combina-
tion with the scaffold used, in order to tune the
expression level to achieve efficient but still mono-
valent display of the POI.
Selected DARPins have favorable biophysical
properties
The selected DARPins retain the favorable bio-
physical properties of the initial library members.13
They can be expressed in large amounts in soluble
form in the cytoplasm of E. coli (Fig. 1b), and
routinely more than 100 mg of protein is purified
from 1 l of shake-flask culture. Of the 84 clones
analyzed by SEC, 46 (55 %) show a single peak at the
elution volume expected for the monomer (Fig. 2)
and another ten (12%) show a single peak at a
greater elution volume, indicating some interaction
with the column material; nevertheless, they were
confirmed to be monomeric by SEC-MALS mea-
surement. The other DARPins are presumably a
mixture of monomer and dimer or elute at higher
apparent molecular mass, indicating oligomeriza-
tion or partial unfolding, as a consequence of some
particular features of the sequence of a given library
member. Because of the diversity of clones isolated
for each target, purely monomeric tight-binding
DARPins have always been found.
The selected clones specifically recognize the
target protein that they were selected on and do
not cross-react with other proteins tested, as shown
by ELISA (Fig. 5c and d). These ELISAs were always
done with recloned non-fused protein, and thus
independent of being fused to the phage coat
protein 3 or being displayed on phage particles.
DARPins with picomolar affinities were selected
on a regular basis
The highest affinities of the selected binders are in
the sub-nanomolar range (Table 3) and thus as good
as the affinities obtained when performing ribosome
display selections with the identical initial DARPin
library.16–18 There are several factors that may con-
tribute to this, at first surprising, observation. First,
the functional size of the present phage library is
very large, and is expected to cover the diversity of
about 1010 members present in the initial ribosome
display library that was used as template.16 There-
fore, the same input library is sampled in ribosome
display and phage display; however, in ribosome
display, mutations continuously increase this diver-
sity during the selection rounds. Second, a growing
experience in designing selection experiments, as
summarized in the optimized selection protocol,
may have improved the quality of the selected
1222 Selection of DARPins with Sub-nanomolar Affinitiesclones. When comparing the performance of phage
display and ribosome display, often no significant
difference was found at the levels of the best binders,
however, the number of different binders with such
characteristics tends to be larger in ribosome dis-
play. We speculate that in early rounds, low-affinity
binders may acquire point mutations in ribosome
display and thus survive later selection rounds with
greater stringency, adding to diversity.
From the comparison of affinities obtained from
various antibody libraries, it is widely accepted that
the affinities of the selected antibodies correlate with
the size of the library.8 From phage antibody frag-
ment libraries containing 107 – 109 members, binders
with affinities of up to 10 nM, and for libraries with
over 5×109 members, binders with sub-nanomolar
affinities have been selected.8 From our phage
DARPin library containing about 1010 functional
members we obtained against all target proteins
multiple DARPins with affinities in the low nano-
molar or, in most cases, even the sub-nanomolar
range (Table 3). These affinities compare very
favorably with those obtained for synthetic antibody
repertoires of similar or even larger size.9–11,33 Our
very promising results can be attributed to the
optimized diversity design of the DARPin library
as well as the high functional display rate of the SRP
phage display system. This will make affinity
maturation unnecessary for most applications.
Broadening diversity of selected DARPins by
epitope masking or removal
One frequently observed phenomenon in phage
display when performing selection experiments on
certain target proteins is low diversity of the selected
binders, even when using large libraries.9,34–36 There
are many reasons why a certain binder might be
selected with preference and dominate the selected
pool: for example, (i) the binder has much higher
affinity than the other binders; (ii) the binder is
displayed more efficiently than the other binders,
(iii) the target protein contains a preferred binding
site on its surface;35 or (iv) there are only limited
epitopes on the target protein accessible to potential
binders, e.g. by extensive glycosylation. When
performing selections on the receptors of the ErbB
family we obtained binders with low diversity (i.e.
focused on a dominant epitope), suggesting that
some epitopes in this family are very well suited for
the DARPin binding interface, such that they
dominated the selection. The dominant DARPin
E_01 was also shown to be displayed at slightly
higher levels than other library members (data not
shown), and both E_01 and B4_02 have very high
affinities, indicating that also the above-mentioned
points (i) and (ii) can influence the selection of
DARPins by phage display. Note that a much
broader diversity was obtained for other targets
(TNFα, huIgG1_Fc, CitS37 and others, data not
shown). We tested several strategies to increase the
diversity of the selected DARPins and to broaden the
range of selected specificities.For ErbB1, where essentially only one binder was
found in the initial selections, and for ErbB4, where
one binder was very dominant (Table 2), we per-
formed one round of selection on the target protein in
the presence of a twofold excess of the purified
dominant binder using pools of phage particles
partially enriched on the target protein as input. This
strategy of epitope-masking was described recently
for antibodies.38,39 In both cases this approach re-
sulted in increased diversity (i.e., binding to different
epitopes) of the binders (Fig. 6). For ErbB1, two of the
three clones analyzed further still bound to the same
or a competing epitope as the binder used for
epitope-masking. This is presumably due to the
low excess, only twofold, of competitor used, leading
to only a partial masking of the epitope, and thus
making it possible to still find binders to the same
epitope.
For the full-length ectodomain of ErbB2 (ErbB2-
631), the selection yielded a pool of binders that
recognize this full length ectodomain but not a
truncated construct lacking domain IV (Fig. 6a).
Therefore, we performed selections on the truncated
version. Probably due to the lower stability of
ErbB2-509, selections on this target protein were
successful only at low temperature. They yielded a
pool of binders recognizing ErbB2-631 as well as
ErbB2-509 (Fig. 6b). Therefore, both strategies,
epitope-masking and epitope removal, were applied
successfully, and combining such binders recogniz-
ing different epitopes would give the possibility of
constructing multivalent binders for a given target
protein.
Conclusions
We have validated our phage DARPin library by
successfully selecting well-behaved and high-affi-
nity binders against a broad range of target pro-
teins. The SRP phage display used in this work has
thus proven to be a powerful method to display
libraries of fast-folding and stable DARPins that
would be refractory to conventional phage display
using the Sec translocation pathway. We envision
that this novel phage display method may be
beneficial for other libraries containing stable and
fast-folding proteins. The addition of phage display
to the selection repertoire for the generation of
specific DARPins further expands the application
range of this novel class of binding molecules.Materials and methods
Materials
All chemicals were of the highest quality available
and were purchased from Fluka (Switzerland) unless
stated otherwise. Oligonucleotides were from Micro-
synth (Switzerland). Vent DNA polymerase, restriction
enzymes and buffers were from New England Biolabs
(USA) or Fermentas (Lithuania). Helper phage VCS
M13 was from Stratagene (USA). All cloning and phage
1223Selection of DARPins with Sub-nanomolar Affinitiesamplification was performed in E. coli XL1-Blue from
Stratagene (USA).
Molecular biology
Unless stated otherwise, all molecular biology methods
were performed according to standard protocols.40
Phagemid and expression vectors
The phagemid pPDV1 (Supplementary Data Fig. 1) is
related to pDST23,21 and comprises the following features:
(i) the signal sequence of E. coli DsbA (DsbAss) ensures
efficient SRP phage display; (ii) sequences for display are
inserted into the multiple cloning site (MCS) between the
DsbAss and the coding sequence of the C-terminal domain
(amino acids 250–406) of protein 3 (p3) of filamentous
phage M13; (iii) the fusion protein (p3 fusion) is under the
control of a lac promoter/operator element and the lacIq
gene provides high levels of the lac repressor in cis; (iv) an
amber stop codon (TAG) is interposed between the
displayed sequence and the C-terminal domain of p3; (v)
the fusion protein contains a Flag-tag; (vi) the vector
carries an f1 origin of replication to permit production of
virions using an appropriate helper phage, such as VCS
M13; and (vii) the vector has a plasmid origin (ColE1 ori)
and an antibiotic-resistance marker (the gene for chlor-
amphenicol acetyl transferase (cat) providing resistance to
cam) to allow propagation as a plasmid in E. coli.
The vector pDST67 was used for high-level, soluble
cytoplasmic expression of the selected DARPins contain-
ing anN-terminalMRGS(H)6 tag. pDST67 is a derivative of
pQE30 (QIAgen) in which the single amber stop codon
(TAG) after theHindIII restriction site has been replaced by
a double stop codon (TAATGA), avoiding the formation of
a read-through product when using suppressor E. coli
strains such as XL1-Blue. pDST67 was generated via PCR
cloning using the oligonucleotides oDST29 5′-GGCCA-
AGCTTAATTAATGACTGAGCTTGGACTCCTG-3′ and
oDST30 5′-AAAGCCAAGCTAGCTTGGATTCTC-3′ and
pQE30 as template. The resulting PCR product was
HindIII/NheI-digested and ligated into the identically
treated and dephosphorylated pQE30 vector. Coding
sequences of the selected DARPins were cloned into
pDST67 via BamHI/HindIII, yielding plasmids termed
pDST67_(DARPin Name). Protein expression and purifi-
cation are described below.
The vector pAT223 (GenBank accession number
AY327138) was used for the expression of fusion proteins
with an N-terminal Avi-tag for in vivo biotinylation,
followed by phage lambda protein D (pD) as fusion pro-
tein, followed by aHis6 tag for IMACpurification and then
the protein of interest, e.g. a DARPin to be biotinylated and
immobilized. Coding sequences of the selected DARPins
E_01 and B4_02 were cloned into pAT223 via BamHI/
HindIII, yielding pDST126 and pDST127, respectively.
Protein production, purification and confirmation of
biotinylation were as described.17
Library construction
The N3C DARPin library in the ribosome display
format13 was PCR amplified using primers introducing a
BamHI and HindIII site (EWT3 and WTC4),16 enabling
subsequent subcloning into phagemid pPDV1. A total of
200 PCR reactions of 50 μl yielded about 600 μg of purified
PCR product, which was ligated after restriction digest ofthe components using BamHI and HindIII into pPDV1.
About 300 μg of ligated and purified DNA was first
transformed by electroporation into MP1 cells (E. coli
strain MC1061)41 containing the F episome transferred
from E. coli XL1-Blue cells) as these cells can be trans-
formed very efficiently,42 yielding 3.6×1010 independent
colonies. From these cells, the plasmid DNAwas isolated
and re-transformed into E. coli XL1-Blue cells, for
subsequent phage production, yielding 2.6×1010 indepen-
dent colonies. The transformed XL1-Blue cells were
infected with helper phage VCS M13, and IPTG was sub-
sequently added to the culture to induce the expression
and thus the display of the DARPins, thereby producing
the phage particles of the phage DARPin library. The
DARPin-displaying phage particles were precipitated
with PEG from the culture supernatant, resuspended in
PBS (137 mM NaCl, 3 mM KCl, 8 mM Na2HPO4, 1.5 mM
KH2PO4, pH 7.4) containing 10% (v/v) glycerol, and
stored at -80 °C, where they were stable for at least 1 year.
Library characterization
To determine the percentage of transformed clones
encoding functional DARPins, 55 randomly picked clones
were sequenced using standard techniques. To analyze the
fraction of DARPin-p3 fusion proteins displayed, phage
particles produced form the 55 sequenced clones were
analyzed by Western blot as described,21 using the anti-
FLAG antibody M1 (Sigma, USA) for detection. Phage
particles displaying an scFv, known to be well displayed
using a conventional phagemid, were used as a reference;
phage particles produced form phagemid pDST24.21 To
quantify the percentage of DARPins showing high-level,
soluble cytoplasmic expression, a pool of DARPin inserts
from the phage library was subcloned into pDST67 via
BamHI/HindIII. Small-scale expression and SDS-PAGE
(15% (w/v) polyacrylamide gel) analysis of 57 randomly
picked clones, which were not sequenced, was performed.
Target proteins
Purified target proteins were used for all experiments
and are described in detail in Table 1. ErbB receptors were
kindly provided by Dr Tim Adams and coworkers
(CSIRO, Melbourne, Australia). The Fc domain of
human IgG1 was purchased from R&D Systems, UK.
For immobilization, aliquots of these target proteins (200–
600 μg) were chemically biotinylated using EZ-Link Sulfo-
NHS-SS-Biotin (Pierce, USA). Due to the size difference of
the target proteins, a variable molar excess of the
biotinylating reagent relative to the target protein was
used (fourfold for huIgG1_Fc, 9-fold for ErbB1, 6-fold for
ErbB2-509, 6-fold for ErbB2-631 and 9-fold for ErbB4).
Reaction conditions were used according to the supplier's
manual (Pierce, USA). Successful biotinylation was con-
firmed by ELISA and Western blot experiments, but the
extent of biotinylation was not quantified.
Non-biotinylated and biotinylated TNFα, shown to be
biologically active, was expressed and purified from E. coli
(C. Zahnd and A.P., unpublished results). In brief, human
TNFα was amplified using the primers rTNFstopHind 5′-
GATGAGAAGCTTTCATTACAGGGCAATGATCCCAA-
AG-3′ and fTNFa 5′-CACCACCATGGCTGTCAGAT-
CATCTTCTCGAAC-3′. The resulting PCR product was
NcoI and HindIII-digested and ligated into the identically
treated and dephosphorylated vector pAT222 (GenBank
accession number AY327137), yielding the construct with
an N-terminal Avi-tag23 used for the expression of bio-
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yielding the construct with no tag used for the expression
of non-biotinylated TNFα. For biotinylation, the biotin-
ligase BirA of E. coli was cotransformed and co-expressed
with the Avi-tagged construct in E. coli XL1-Blue to yield in
vivo biotinylated TNFα as described23. The biotinylated
TNFα was purified via a monomeric avidin column. To
allow intramolecular disulfide bond formation, the solu-
ble protein was dialyzed against TBS (20mMTris, 150mM
NaCl, pH 7.6) containing 1 mM reduced glutathione
(GSH) and 0.2 mM oxidized glutathione (GSSG). The
trimeric species was obtained by preparative gel-filtration
chromatography in using TBS as the running buffer. The
TNFα construct with no tag was expressed in E. coli XL1-
Blue, purified via a cation-exchange column using wash-
ing buffer (100 mM MES, pH 5.8) with a NaCl gradient
from 150 mM – 1M, followed by a dialysis step against the
GSH/GSSG buffer mentioned above and subsequent
preparative gel-filtration chromatography. The biological
activity of both constructs was shown by their cytolytic
activity on L929 mouse fibroblast cells (ATTC, USA) and
compared to commercial TNFα. Since the specific activity
was the same within experimental error, and since
disulfide-deficient mutants are known to show reduced
biological activity,43,44 we assume that the disulfides have
been formed correctly.
Immobilization of target proteins
Target proteins had to be immobilized for selection and
ELISA experiments. To avoid partial protein denaturation
of the target proteins that may result from direct immo-
bilization on solid plastic (i.e. polystyrene) surfaces,
biotinylated target proteins were bound to neutravidin or
streptavidin, which had been immobilized directly on a
solid plastic surface, as follows: neutravidin (66 nM,
100 μl/well, Pierce, USA) or streptavidin (66 nM, 100 μl/
well Sigma, Switzerland) in PBS was immobilized on
MaxiSorp plates (Nunc, Denmark) by incubation at 4 °C
overnight. The wells were blocked with 300 μl of PBSTB
(PBS containing 0.1% Tween-20, 0.2% BSA) for 1 h at room
temperature. Binding of the biotinylated target proteins
(100 μl, ∼ 100 nM for selection and ∼20 nM for ELISA) in
PBSTB was allowed to occur for 1 h at 4 °C.
For the first selection round on immobilized target
protein, requiring larger volumes, neutravidin (66 nM,
4 ml/tube) in PBS was immobilized on MaxiSorp Immu-
notubes (Nunc, Denmark) by incubation at 4 °C overnight.
The tubes were blocked with 4 ml of PBSTB for 1 h at room
temperature. Binding of the biotinylated target proteins
(4 ml, ∼100 nM) in PBSTB was allowed to occur for 1 h at
4 °C.
For selection on immobilized target protein, neutravidin
and streptavidin were used alternately in selection rounds
to avoid selection of binders against these proteins.
Selection of phage DARPins
Unless stated otherwise, all steps of the phage display
selection were done at room temperature. Selection
rounds were performed either on biotinylated target
protein in solution with subsequent capturing on strepta-
vidin-coated magnetic beads (referred to as: target protein
in solution) or on biotinylated target protein bound to
neutravidin or streptavidin, which had been immobilized
directly on a solid plastic surface (referred to as immo-
bilized target protein), as described below. Very good
results were obtained when performing the first selectionround of selection on immobilized target protein, pre-
sumably because of the greater efficiency of capturing
binders (especially important in the first round), followed
by further rounds on target protein in solution, presum-
ably because of the lower enrichment of background
binders (for the optimized selection protocol, see Supple-
mentary Data). Protocols were adapted from Ref. 45.Selection on target proteins in solution
When the first selection cycle was done in solution,
about 2.5×1013 phage particles of the phage DARPin
library were incubated for 1 h with 100 nM biotinylated
target protein in 2 ml of PBSTB for the first round of
selection. In subsequent selection rounds, about 1012 phage
particles were used (see below). The phage–antigen
complexes were then captured on 100 μl streptavidin-
coated paramagnetic beads (10 mg/ml, Dynabeads
MyOne Streptavidin T1, Dynal) for 20 min. After washing
the beads eight times with PBST (PBS, 0.1% Tween-20) the
phage particles were eluted with 200 μl of 100 mM
triethylamine (Et3N, pH not adjusted) for 6 min, followed
by 200 μl of 100 mM glycine-HCl, pH 2, for 10 min. Eluates
were neutralizedwith 100 μl of 1MTris–HCl, pH 7, or 18 μl
of 2 M Tris-base, respectively, combined and used to infect
5 ml of exponentially growing E. coli XL1-Blue cells. After
shaking for 1 h at 37 °C, cells were expanded into 50 ml of
fresh 2YT medium (5 g of NaCl, 10 g of yeast extract, and
16 g of tryptone per liter) containing 10 μg/ml cam and
incubated at 37 °C with shaking. After a maximum of 5 h
(shorter times if A600=0.5 was reached earlier), isopropyl-
β-D-thiogalactopyranoside (IPTG) was added to a final
concentration of 0.2 mM and 15min later the phage library
was rescued by infection with VCS M13 helper phage at
1010 pfu (plaque-forming units) per ml (multiplicity of
infection ∼ 20). Cells were grown overnight at 37 °C
without the addition of kanamycin. Cells were removed by
centrifugation (5600g, 4 °C, 10min) and 40ml of the culture
supernatant was incubated on ice for 1 h with one-fourth
volume of ice-cold PEG/NaCl solution (20 % (w/v)
polyethyleneglycol (PEG) 6000, 2.5 M NaCl). The pre-
cipitated phage particles were then collected by centrifu-
gation (5600g, 4 °C, 15 min) and redissolved in 2 ml of PBS
and used for the second round of selection.
For the subsequent selection rounds, about 1012 of the
amplified phage particles were used as input and
incubated with 100 μl of streptavidin-coated paramagnetic
beads for 1 h to remove unspecific and streptavidin-
binding phage particles. After removing the beads, phage
particles were incubated for 1 h with 100 nM biotinylated
target protein, complexes were captured on fresh beads,
beads were washed 12 times with PBST, phages eluted
with 400 μl of 100 mM glycine-HCl, pH 2, for 10 min, the
eluate neutralized with 36 μl of 2 M Tris-base and phage
particles amplified and purified as described above.
After three rounds, enrichment of phage particles
displaying DARPins binding specifically to the target
protein was monitored by phage ELISA. About 5×1010
phage particles (estimated spectrophotometically46) of the
initial library and the amplified pools of each selection
round were pipetted into wells with and without immo-
bilized target protein and kept at room temperature for
2 h. After washing the wells four times with 300 μl of
PBST, bound phage particles were detected with mouse
anti-M13 antibody horseradish peroxidase conjugate
(Amersham Pharmacia Biotech, UK) and soluble BM
Blue peroxidase (POD) substrate (Roche Diagnostics,
Germany).
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For the first selection cycle about 3.5×1013 phage
particles of the phage DARPin library were added to an
immunotube containing the immobilized target protein
(biotinylated target protein bound to neutravidin, which
had been immobilized directly on the solid plastic surface)
and incubated with rotation for 2 h. After rinsing the tube
ten times with PBST, the phage particles were eluted with
500 μl of 100 mMEt3N (pH not adjusted) for 6 min, follow-
ed by 500 μl of 100 mM glycine-HCl, pH 2, for 10 min.
Eluateswere neutralizedwith 250 μl of 1MTris–HCl, pH7,
or 45 μl of 2 M Tris-base, respectively, combined and used
to infect 13 ml of exponentially growing E. coli XL1-Blue
cells. After shaking for 1 h at 37 °C cellswere expanded into
130 ml of fresh 2YTmedium containing 10 μg/ml cam and
incubated at 37 °C with shaking. Phage amplification and
precipitation was done as described above.
In the subsequent selection rounds about 1012 of the
amplified phage particles were first incubated in a blocked
immunotube (coated either with neutravidin or streptavi-
din used for immobilization of the target protein in the
previous round of selection and BSA) for 1 h to remove
neutravidin, streptavidin or unspecific binding phage
particles. For the binding selection, the phage particles
were incubated for 1 h in four wells containing the
immobilized biotinylated target protein (directly coated
neutravidin or streptavidin were used alternately in
subsequent selection rounds). The wells were washed 12
times with PBST, phages eluted from each well with 100 μl
of 100 mM glycine–HCl, pH 2, for 10 min, the combined
eluates neutralized with 36 μl of 2 M Tris base and phage
particles amplified and purified as described above. After
three rounds, enrichment was determined by phage
ELISA as described above.Selection with epitope-masking
The respective DARPins used for the epitope masking
were expressed in 50 ml shaking flask cultures and
purified by IMAC as described.13 Pools of phage particles
already partially enriched for binders against the respec-
tive target protein (one or two rounds of selection on the
target protein alone as described above) were used as
input. Biotinylated target protein (100 nM) was pre-
incubated for 1 h with the respective DARPin (200 nM
or 2 μM) before performing a standard selection round on
soluble target protein as described above. After one round
of selection with epitope-masking, amplified phage
particles were analyzed by phage ELISA. Binding to
immobilized target protein alone and in the presence of an
excess of the respective DARPin (2 μM) used for epitope-
masking was done as described above.Screening of single clones
From the selected phage pools showing specific binding
to the respective target protein, the DNA fragments
encoding the DARPin inserts were subcloned into the
expression vector pDST67 via BamHI/HindIII.
Single selected DARPins were expressed in 96-deepwell
plates. In brief, 1.2ml of 2YTmedium containing 1% (w/v)
glucose and 50 μg/ml ampicillin was inoculated with a
single, randomly picked colony of E. coli XL1-Blue
harboring pDST67 encoding one of the respective selected
DARPins and incubated overnight at 37 °C with shaking.
Fresh 2YTmedium (1.1ml) containing 50 μg/ml ampicillinwas inoculated with 100 μl of the overnight culture. After
incubation at 37 °C for 1–2 hwith shaking, 100 μl of 6.5mM
IPTG in 2YT was added to each well and protein
expression was continued for 4 h. Cells were harvested
by centrifugation, resuspended in 50 μl of B-PER II (Pierce,
USA) by vigorous shaking for 20min at room temperature.
Then, 950 μl of PBSTB was added and cell debris was
removed from the crude extract by centrifugation.
For the ELISA, 10–100 μl of the above crude extracts was
applied to wells with or without immobilized target protein
and incubated at room temperature for 1 h. After washing
the wells three times with 300 μl of PBSTB, wells were incu-
bated with an anti RGS-His antibody (QIAgen, Germany)
(1:5,000 in PBSTB, 1 h at room temperature), as primary
antibody. A goat anti–mouse IgG alkaline phosphatase
conjugate (Sigma, USA) (1:10,000 in PBSTB, 1 h at room
temperature) was used as secondary antibody. The bound
DARPins were detected with the substrate di-sodium 4-
nitrophenyl phosphate (pNPP, 3 mM) (Fluka, Switzerland)
in buffer containing 50 mM NaHCO3 and 50 mM MgCl2
(Fig. 1b).
The 96-well purification of DARPins
Selected DARPins identified as binders were expressed in
96-deep well plates as described above. Eight plates
containing fresh 2YT medium were inoculated in parallel
with the overnight culture, resulting in a total expression
culture volume of about 10 ml for each clone. Cells were
lysed as described above, the 400 μl B-Per II lysates for each
clone were pooled and 400 μl of TBS500 (50 mM Tris–HCl,
pH 8, 500 mM NaCl), containing 20% (v/v) glycerol and
40 mM imidazole, were added. After centrifugation the
cleared lysates were used for the 96-well IMAC purification
(SwellGel Nickel Chelated Discs, 96-well filter plate, Pierce,
USA) according to the supplier's manual, yielding, on ave-
rage, more than 1 mg ofN 95% pure protein for each clone.
Purified proteins were used for all further experiments.
Analytical size-exclusion chromatography (SEC)
All IMAC-purified DARPins were analyzed at a con-
centration of 10 μM on a Superdex 75 gel-filtration
chromatography column (Amersham Pharmacia Biotech,
USA) using a Pharmacia SMART system at a flow-rate of
60 μl/min and with PBS as the running buffer (Fig. 2).
Phage protein D (gpD) with an apparent mass of 17.6 kDa
and phage protein SHP, a trimer with an apparent mass of
50.2 kDa, were used as molecular mass standards.
A subset of DARPins showing too high or too low an
elution volume in SEC were further analyzed by SEC
multi-angle light-scattering (SEC-MALS) as described.37
Competition ELISA measurements
Biotinylated target proteins were bound to neutravidin,
which had been immobilized directly onto aMaxiSorpplate
as described above. For competition, purified DARPins
were incubated with various amounts of non-biotinylated
target protein present before (1 h at room temperature) and
during the binding reaction (12 min at room temperature).
After washing the wells three times with 300 μl of PBSTB,
wells were incubated with an anti RGS-His antibody
horseradish peroxidase conjugate (QIAgen, Germany)
(1:5,000 in PBSTB, 1 h at room temperature) and the
bound DARPins were detected with soluble BM Blue POD
substrate (Roche Diagnostics, Germany).
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Biotinylated target proteins as well as biotinylated
DARPin-pD fusions (see above) were bound to neutravi-
din, which had been immobilized directly onto a
MaxiSorp plate as described above. To the wells with
immobilized DARPin-pD fusions the respective non-
biotinylated target protein (100 μl, ∼20 nM) in PBSTB
was added for binding for 1 h at 4 °C. Purified non-
biotinylated DARPins (100 μl, ∼50 nM) were used for the
binding reaction (1 h at room temperature) and detection
of bound DARPins was done as described for the ELISA
using crude cell extracts (see above).
Surface plasmon resonance (SPR)
SPR was measured by using a BIAcore 3000 instrument
(BIAcore, Sweden). All measurements were done in HBST
buffer (20 mMHEPES, 150 mMNaCl, 3 mM EDTA pH 7.4,
0.005% Tween-20) at a flow rate of 50 μl/min throughout.
The following amounts of biotinylated target protein
described in Table 1 were immobilized on SA chips
(BIAcore): ErbB1 (1000 RU), ErbB2-509 (400 RU), ErbB4
(600 RU), huIgG1_Fc (500 RU). For the determination of
kinetic data, the interactions were measured as follows:
5 min initial buffer flow, followed by a 2 – 15 min injection
of DARPin at different concentrations (1 nM – 250 nM)
and a final off-rate measurement of 10 to 75 min with
buffer flow. The signal of an uncoated reference cell and
buffer response was always subtracted from the senso-
grams (double referencing). The kinetic data of the
interaction were evaluated with a global fit using Scrubber
2 (BioLogic Software Ltd, USA). (All sensorgrams are
shown in Supplementary Data Fig. 2.)Acknowledgements
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